Objective: In the present study we investigated the role of hematological parameters, including neutrophil/lymphocyte ratio and platelet/lymphocyte ratio, mean platelet volume and platelet distribution width in the evaluation of treatment efficacy in adult patients diagnosed with cutaneous leishmaniasis.
INTRODUCTION
Leishmaniasis is a group of mammalian diseases caused by the intracellular parasites of the genus Leishmania and transmitted during blood-feeding by infected female sand flies (phlebotomus). Leishmaniasis is an important health issue affecting approximately 12 billion people in 88 countries around the world. The parasites enter the body through the skin and infect the cells of the reticuloendothelial system. The severity of disease results in varying clinical manifestations. The most common form is cutaneous leishmaniasis (CL).
1,2 Routine CBC parameters, such as white blood cell count (WBC), neutrophil, lymphocyte and platelet counts, red cell distribution width (RDW), mean platelet volume (MPV), and platelet distribution width (PDW), are used in many settings, including the evaluation of systemic inflammation and the diagnosis and treatment of disease. Recent studies have reported changes in the circulating neutrophil, lymphocyte, and platelet counts, WBC count, MPV, PDW, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in cancer, inflammatory disease, and infection. Hematological changes are closely associated with the severity and the prognosis of disease. [3] [4] [5] No previous study has evaluated standard hematological parameters such as NLR, PLR, RDW, WBC, MPV, and PDW in CL patients. As a result, the present study aimed to establish changes in neutrophil, lymphocyte, and platelet counts, RDW, WBC, MPV, PDW, and the NLR and PLR in CL patients.
METHODS
The present study included 45 adult patients aged 18 to 76 years who were free of comorbid chronic systemic diseases and who had been diagnosed with CL based on clinical and laboratory evaluation and were followed as inpatients in the Dermatology clinic between January 2011 and December 2014. A control group consisting of 45 healthy adults aged 21 to 66 who were admitted at the outpatient dermatology clinic was also included in the study. Controls were randomly selected among healthy adults and were matched to the patient group by sex and age. In our dermatology clinic, patients with lesions greater than 2-5 cm and with inflammation located in the joints and the cartilage, patients with lesions resulting in chronic cosmetic problems, the patients with lesions located on the face, such as the eyelids and lips, causing dysfunction and deformity, or CL patients with multiple (> 5) lesions were treated as inpatients. Blood samples were obtained from the antecubital vein and collected in vacuum tubes containing EDTA (15% K3 EDTA 0.054 ml / 4.5 ml blood) and were tested within one hour. Complete blood counts were performed by an automated complete blood counter (Cell Dyn 3700). The age and gender of the patients and the pre-and posttreatment WBC, neutrophil, platelet and lymphocyte counts, NLR and PLR, RDW, PDW, and MPV were recorded and compared between the study groups.
Statistical analysis of the data was performed using the SPSS 15.0 package (SPSS for Windows 15, Chicago, Illinois, USA). Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as percentages (%). Categorical variables and continuous variables were evaluated using the chi-square test and Student's t-test, respectively. Numeric data were compared using the Kruskal-Wallis test, and intra-group comparisons were made using the Mann-Whitney U-test. A P-value < 0.05 was considered statistically significant.
RESULTS
Among the 45 patients diagnosed with CL, 31 (68.9%) were female and 14 (31.1%) were male. The age of the patients ranged from18 to 76 years. The mean age of the patients was 46.73 ± 18.35 years. The control group consisted of 45 subjects ranging in age from 21 to 66 years, and included 17 (37.8%) male and 28 (62.2%) female patients. The mean age of the healthy subjects was 46.0 ± 13.0 years.
The most common localization of the lesion was the nose, upper extremity (forearm, dorsal hand) and cheeks ( Figure 1 ). The number of lesions in a single patient ranged from 1 to 10; the mean lesion number was 2.7. The duration of disease ranged from one to 36 months and the mean duration of disease was 8.7 ± 8.6 months. Intramuscular (IM) meglumine antimoniate (Glucantime) 10-20 mg/kg/ day was administered in 37 patients. Intravenous (IV) sodium stibogluconate (Pentostam) 10-20 mg/ kg/day was administered in 10 patients. Both Glucantime and Pentostam were administered to two patients. Patients received Glucantime/Pentostam at a mean dose of 13.8 day. The demographics and the clinical features of the patients are summarized in Table 1 .
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Patient (n) (Mean)
Ear 2 Nose 17 Lip 1
Upper extremity 14
Lower extremity 5
Similar disease history 3
Meglumine antimonate IM 37
Sodium stibogluconate IV 10
Average dose (day) 13.77 Figure 1 . Erythematous, ulcerated nodular lesions covered with black crusts on nose, upper extremity, forehead and cheek. When the pre-and post-treatment hematological results were compared among the patients and control subjects, WBC, neutrophil, and lymphocyte counts were significantly reduced among the patients. PDW, RDW, NLR, and PLR were significantly elevated in the patient group. There was no significant difference in platelet count or MPV among the study groups. When the pre-and post-treatment hematological results were compared among the patients, pre-treatment WBC, lymphocytes, and platelets were significantly increases, whereas the eosinophils, and NLR and PLR were significantly lower prior to clinical treatment of the disease. There was no significant correlation between neutrophil, MPV, PDW, and RDW (Tables 2, and 3). 
Patient (n) (Mean)
DISCUSSION
Leishmaniasis is an important public health issue affecting billions of people around the world. 1 Leishmaniasis is endemic in Southeastern Anatolia and in the Mediterranean regions of Turkey, and is considered a major health challenge.
1 The disease has a wide clinical spectrum that includes asymptomatic disease, cutaneous, mucocutaneous, and visceral leishmaniasis as a result of various parasite-and host-related factors. Leishmaniasis lesions begin as an erythematous papule and develop into a nodule of 1-2 cm in diameter within a few months. Later, this nodule progresses to an ulcerative lesion that may be crusted over. If left untreated, these lesions can heal spontaneously within 1-1.5 years. However, scarring in patients with lesions located on the face, especially the nose, ears, and eyelids, often results in cosmetic problems and facial dysfunction.
1,2
Recent studies on the pathogenesis of Leishmaniasis have shown that neutrophils migrate to the infection site within the first 30 minutes following the passage of the parasite into the body and begin to phagocytose parasites at the site of infection. Neutrophils facilitate parasite elimination through the secretion of cytokines, chemokines, LTB-4, and neutrophil-derived extracellular antimicrobial peptides. Additionally; reduced acute neutrophilic infiltration results in improved host defense against the parasite.
6-8 Furthermore, the clinical course of the disease is characterized by the balance between the activation of a set of cytokines (IL-2, IFN-γ, TNF-α), most of which are produced by Th-1 T-cells, and the deactivation of other cytokines (IL-4, IL-5, IL-13) produced by the other regulatory T-cells. 2, 8, 9 Hematological disorders may also occur in cases of systemic leishmaniasis and may include anemia, thrombocytopenia, and pancytopenia.
1 Previous studies have reported that neutropenia occurs in leishmaniasis due to the destruction of neutrophils in the enlarged spleen and changes in the circulating polymorph nuclear leukocytes (PNL). Pancytopenia develops as a result of the rapid destruction of blood cells covered with membrane-derived antiplatelet, anti-neutrophilic and anti-erythrocyte IgG antibodies. A significant reduction in the bone marrow PNL reserve has been reported to occur in some patients. Anemia is believed to result from ineffective erythropoiesis and the phagocytosis of immature erythroblasts caused by macrophage hyperactivity in the bone marrow. 10, 11 The lymphocyte count is reduced due to increased lymphocyte apoptosis in cases of chronic infection. Again, an ongoing inflammatory process results in an increased number of megakaryocytes and a relative thrombocytosis.
12
Recently, several markers have been in used to measure the systemic inflammatory state. The NLR has been used to evaluate the systemic inflammatory response in many conditions, including cardiovascular diseases, diabetes mellitus, metabolic syndrome, local or systemic infection, and cancer (lung, ovarian, and colorectal).
13-15 Sen et al. Reported increased neutrophil count and NLR, and reduced lymphocyte count among patients with psoriasis relative to a control group. 14 Ataseven et al. conducted a study involving 104 psoriasis patients demonstrating significant elevations in leukocyte and neutrophil counts and the NLR among the patient group. 16 The authors suggested that hematologic parameters might be used as a simple, affordable, and useful marker for disease follow-up and the assessment of systemic inflammation in psoriasis. Lymphocyte count and NLR were correlated with parasitemia in a study of 440 Dutch patients diagnosed with malaria; however blood count data was not a significant marker of clinical severity in patients treated in the intensive care unit. Evaluation of the NLR together with lymphocytopenia was a more effective marker of bacteremia than the total leukocyte count and CRP. 17 A Japanese study of 266 hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy was reported an improved response to treatment among patients with lower NLR. NLR may be a useful marker for evaluating the response to treatment.
18 Gokmen et al. conducted a study involving 96 ankylosing spondylitis patients and 81 healthy subjects, measuring NLR before and after anti-TNF-α treatment. Pre-treatment NLR was higher in the patients relative to the control group, whereas post-treatment NLR was reduced relative to control subjects. NLR was therefore beneficial in evaluating the efficacy of anti-TNF-α treatment in suppressing inflammation when used in combination with other acute phase reactants such as CRP. 19 No previous studies have evaluated NLR in CL. The present study demonstrates that both pre-and post-treatment NLR is higher among Leishmaniasis patients relative to the control group. NLR was increased following treatment. WBC, neutrophil, and lymphocyte counts were lower compared to the control group in both the pre-and post-treatment samples. These results are consistent with prior studies conducted in other diseases.
MPV is one of the most commonly studied markers of platelet activation. Recently, new platelet indicators such as PDW, a quantitative marker of platelet volume, have been evaluated as prospective markers of platelet activation.
20 Previous studies have shown that increased MPV reflects both systemic inflammatory activity and the treatment response, and is closely correlated with local inflammation. 21 Previous studies have demonstrated that MPV is increased in cardiovascular diseases such as myocardial infarction, stroke, and peripheral arterial disease, whereas it is unclear what changes may occur in rheumatic diseases. PDW is useful in distinguishing reactive thrombocytosis and essential thrombocythemia. 22, 23 PLR is associated with poor prognosis in several cancers and cardiovascular diseases. 24 Yuce et al. evaluated MPV before and after the cobalamin treatment in 204 patients with vitamin B12 deficiency, and reported that MPV is significantly increased post-treatment, whereas the platelet count is decreased. 25 An Iranian study established higher platelet counts and lower MPV levels in the active period of inflammatory and infectious diseases relative to the recovery period in a study of 100 pediatric patients. They suggested that these markers may be used as reliable markers of disease activity and for evaluation of the treatment response. 4 A study by Bozkurt et al. investigated pre-and post-treatment MPV and RDW levels in patients with brucellosis, reporting decreased MPV and RDW during the pre-treatment phase relative to the post-treatment period. Again, ESR, MPV, RDW, hemoglobin, CRP, PLT, and WBC differed significantly among the study groups. 5 Boyraz et al. Evaluated 105 ankylosing spondylitis (AS) patients receiving anti-TNF-α treatment and found no significant difference in NLR compared to the control group. However, they reported a significant reduction in PLR. TPLR may be a useful marker for clinical follow-up and the identification of sub-clinical inflammation in AS patients. 24 Another study evaluated rheumatoid arthritis patients in remission and included both and found a significant difference in the platelet, lymphocyte, and neutrophil counts in anti-TNF-α treated patients relative to healthy subjects, whereas there was no significant difference in NLR and PLR. Based on these findings, they concluded that anti-TNF-α treatment achieved a complete inflammatory suppression in RA patients. 26 Kılıncalp et al. evaluated144 patients diagnosed with colorectal cancer, reporting that NLR, PLR, and the MPV levels were significantly elevated in the patient group. The authors suggested that this parameter might be used at the postoperative follow-up and in general population screening. 15 No previous study has evaluated MPV, RDW, and PLR in patients with CL. We found that pre-treatment PLR and PDW are higher among leishmaniasis patients relative to the control group, whereas MPV levels are not significantly different. Additionally, pre-treatment PLR was lower compared to the post-treatment group.
In conclusion, parameters measured during routine CBC testing, such as PLR, WBC, neutrophil count, RDW, PDW, and MPV may be used as markers of the inflammatory state in patients with CL. Furthermore, we suggest that these parameters may provide insight in the evaluation of early treatment efficacy. However, large-scale studies are required to further clarify the use of these parameters in clinical practice. 
DISCLOSURES
Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.
